Skip to Main content Skip to Navigation
Journal articles

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Constance Delaby 1, 2, 3, 4 Charlotte Teunissen 5, 6 Kaj Blennow 7 Daniel Alcolea 3, 4 Ivan Arisi 8 Elodie Bouaziz Amar 9 Anne Beaume 10 Aurélie Bedel 11 Giovanni Bellomo 12 Edith Bigot‐corbel 13 Maria Bjerke 14, 15 Marie‐céline Blanc‐quintin 16 Mercè Boada 17, 18 Olivier Bousiges 19, 20, 21 Miles Chapman Mari Demarco 22 Mara d'Onofrio 8 Julien Dumurgier 9 Diane Dufour-Rainfray 23, 24 Sebastiaan Engelborghs 14, 15 Hermann Esselmann 25 Anne Fogli 26 Audrey Gabelle 1 Elisabetta Galloni Clémentine Gondolf 27 Frédérique Grandhomme 27 Oriol Grau‐rivera 28 Melanie Hart Takeshi Ikeuchi 29 Andreas Jeromin Kensaku Kasuga 29 Ashvini Keshavan Michael Khalil 30 Peter Körtvelyessy 31, 32, 33, 34 Agnieszka Kulczynska‐przybik 35 Jean‐louis Laplanche 9 Piotr Lewczuk 35, 36, 37 Qiao‐xin Li 38 Alberto Lleó 4, 3 Catherine Malaplate 39 Marta Marquié 17, 18 Colin Masters 38 Barbara Mroczko 35 Léonor Nogueira 40 Adelina Orellana 17, 18 Markus Otto 41 Jean‐baptiste Oudart 42 Claire Paquet 9 Federico Paolini Paoletti 12 Lucilla Parnetti 12 Armand Perret‐liaudet 43, 44 Katell Peoc'H 45 Koen Poesen 46 Albert Puig‐pijoan 28 Isabelle Quadrio 43, 44 Muriel Quillard‐muraine 47 Benoit Rucheton 48, 49 Susanna Schraen 50, 51 Jonathan Schott Leslie Shaw 52 Marc Suárez‐calvet 28 Magda Tsolaki 53 Hayrettin Tumani Chinedu Udeh‐momoh 54 Lucie Vaudran 55, 56 Marcel Verbeek 57 Federico Verde Lisa Vermunt 5, 6 Jonathan Vogelgsang 25, 58, 59 Jens Wiltfang 25, 34, 60 Henrik Zetterberg 7, 61, 62, 63 Sylvain Lehmann 1, 2 
Abstract : Introduction: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. Methods: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. Results: The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. Discussion: This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-reims.fr/hal-03599269
Contributor : Jean-Marc FEREZ Connect in order to contact the contributor
Submitted on : Thursday, April 7, 2022 - 11:41:24 AM
Last modification on : Tuesday, September 27, 2022 - 4:12:59 AM
Long-term archiving on: : Friday, July 8, 2022 - 6:42:13 PM

File

Alzheimer s Dementia - 2021 - ...
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Citation

Constance Delaby, Charlotte Teunissen, Kaj Blennow, Daniel Alcolea, Ivan Arisi, et al.. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's & Dementia , The Journal of the Alzheimer's Association, In press, ⟨10.1002/alz.12545⟩. ⟨hal-03599269⟩

Share

Metrics

Record views

49

Files downloads

27